Open AccessSerum Exosomal miRNA Might Be a Novel Liquid Biopsy to Identify Leptomeningeal Metastasis in Non-Small Cell Lung Cancer
Author(s) -
Yong Song,
Ye Liang,
Litang Huang,
Liqun Zhou,
Xi Chen,
Mingxiang Ye,
Guannan Wu,
Ping Zhan,
Tangfeng Lv,
Yong Song
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s291611
Subject(s) - exosome , liquid biopsy , lung cancer , microvesicles , medicine , microrna , cd63 , pathology , biopsy , cancer , metastasis , oncology , biology , gene , biochemistry
The survival time of patients with leptomeningeal metastasis (LM) of lung cancer is very short, and the clinical characteristics of LM are varied, making the clinical diagnosis difficult. At present, a positive CSF fluid (CSF) cytology result remains the gold standard for diagnosing LM in lung cancer; however, the process of collecting CSF is traumatic and far less convenient than blood collection. With the development in technology, an increasing number of studies prefer to use liquid biopsy to diagnose or predict the occurrence of the disease. Therefore, we aimed to explore whether serum exosomal miRNA can replace miRNA from CSF to identify or predict the occurrence of LM.